is-159

SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM, respectively, and reduces food intake and body weight.

Biotin (S)-sulfoxide is an inactive metabolite of the coenzyme biotin .1,2It has also been found inE. coliand is reduced by the biotin sulfoxide reduction system as a source of biotin.3 1.Denkel, L.A., Rhen, M., and Bange, F.-C.Biotin sulfoxide reductase contributes to oxidative stress tolerance and virulence in Salmonella enterica serovar TyphimuriumMicrobiology (Reading)159(Pt 7)1447-1458(2013) 2.Carling, R.S., and Turner, C.Methods for assessment of biotin (Vitamin B7)Laboratory assessment of vitamin status193-217(2019) 3.del Campillo-Campbell, A., Dykhuizen, D., and Clearly, P.P.Enzymic reduction of d-biotin d-sulfoxide to d-biotinMethods Enzymol.62379-385(1979)

Dazopride [LY-237733, AHR-5531] is an antiemetic agent with the chemical composition C15H15N5O2S and a molecular weight of 329.38 g/mol. It appears as white to off-white crystalline powder, melting at 159–162°C, and is soluble in water (forceps method) and organic solvents (chlorinated solvents).

FMF-04-159-2 is a potent covalent cell cycle protein-dependent kinase 14 (CDK14) inhibitor with IC₅₀ of 39.6 nM for CDK14 and 256 nM for CDK2.FMF-04-159-2 is able to reduce α-synuclein (α-Syn ) aggregation in neurons and plays a role in Parkinson's disease models, and also inhibits triple-negative breast cancer (TNBC) progression and metastasis by attenuating Wnt/β-catenin signaling.

JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19. JH-XI-10-02 is a potent and selective degrader of CDK8, with an IC50 of 159 nM, based on PROTAC.

CV-159 is a distinctive dihydropyridine Ca2+ antagonist exhibiting anti-inflammatory properties and possessing anti-calmodulin (CaM) activity.

SMD-3236 is a PRAOTAC degrader targeting SMARCA2, designed using SMARCA ligand and VHL-1 ligand, and exhibits prolonged anti-tumor activity in vivo. SMARCA2 acts as a synthetic lethal target in cancer cells lacking SMARCA4, with SMD-3236 showing 2000-fold selectivity for SMARCA2 over SMARCA4, having a DC50 of less than 1 nM and a Dmax of over 95%. In the human cancer xenograft models deficient in SMARCA4, notably the H838 model, SMD-3236 effectively induces loss of SMARCA2 in tumor tissue while sparing the SMARCA4 protein, thereby inhibiting tumor growth. The compound consists of a target protein ligand (red part) SMI-1074, a PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate, and an E3 ligase ligand (blue part) SMARCA2 ligand-14, forming the E3LigaseLigand-linker Conjugate 159.

E3 Ligase Ligand-linker Conjugate 159 is a compound designed as an E3 ligase ligand-linker conjugate. It serves a role in the synthesis of SMD-3236, a PRAOTAC aimed at the targeted degradation of SMARCA2, demonstrating prolonged antitumor efficacy in vivo.

EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.

U75302 is an antagonist of thymosin beta-4 (TB4) receptor with a Ki value of 159 nM on guinea pig lung membranes.

Erythromycin 2'-propionate is a macrolide antibiotic and an esterified form of erythromycin .1It is active againstS. aureuswhen used at a concentration of 1 μg/ml. Erythromycin 2'-propionate (1 mM) inhibits protein synthesis in a cell-free assay. 1.Tardrew, P.L., Mao, J.C.H., and Kenney, D.Antibacterial activity of 2'-esters of erythromycinAppl. Microbiol.18(2)159-165(1969)

anti-TNBC agent-1 is a highly effective compound specifically targeting and combating triple-negative breast cancer (TNBC), demonstrating remarkable potency against various breast cancer cell types with IC50 values ranging from 0.20 μM to 0.27 μM. Its mechanism of action involves inducing apoptosis in SUM-159 cells through the mitochondria pathway and causing G1 phase arrest in these cells.

ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor that inhibits β-catenin reporter activity with an IC50 of 2.9 nM.

DJ-V-159 is a GPRC6A agonist, targeting the G protein-coupled receptor family C group 6 member A (GPRC6A).

AZ-PFKFB3-67 quarterhydrate is a selective and potent inhibitor of the metabolic kinase PFKFB3 kinase, acting on PFKFB3 (IC50: 11 nM), PFKFB2 (IC50: 159 nM) and PFKFB1 (IC50: 1130 nM).

Compound 6d (Antibacterial agent 159) is an antibiotic effective against impetigo and Clostridium difficile infection (CDI), with no observed recurrence for CDI and minimal impact on the beneficial gut microbiome [1].

Ovalbumin (154-159), a peptide fragment derived from ovalbumin, acts as a potent inhibitor of the angiotensin-converting enzyme (ACE) and is utilized in hypertension research [1] [2].

Compound 159, an IL-17 modulator 2, is an orally active modulator of IL-17 that significantly reduces IL-6, IFN-γ, and edema, and can be used in arthritis studies [1].

Anti-Mouse MHC Class I (H-2Kd) Antibody (HB-159) is an IgG2a, κ inhibitor antibody derived from mice that targets mouse MHC Class I molecules.

3-Methyl-1H-pyrrole has a Kd value of 159 μM for t4 lysozyme, as determined by molecular docking, and is widely used in biochemical experiments and drug synthesis research.